| |
 |
Business Week Showcases CVBT!
|
 |
Dear Reader,
In a market populated by bright ideas and bold optimism it’s often difficult for a company’s genuine successes to stand out amid a chorus of hyperbole. In fact, it can be most difficult for companies endeavoring in the trenches to have their watershed moments be fully appreciated.
So, when a leading publication identifies both the increasing interest in an industry and a company’s rising stature therein, it should signal to investors that this company greatly exceeds the run-of-the-mill upstart. Such was the case for CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) which was prominently discussed in an intriguing article in Business Week regarding their core technology’s applications in angiogenesis, the science of enabling the human body to grow new blood vessels.
The Business Week article should foster interest in this heavily funded/heavily followed research arena and by extension for the companies featured in the story. It’s a must-read for anyone interested in biotechnology and the incredible potential of angiogenesis. It’s also interesting to note that the author says that CVBT may be "well ahead of the pack in developing an effective and economic angiogenic therapy—and setting new standards for cardiac care.”
Here's a Link to the Business Week Story.
a
|
Thanks for Reading StockUpTicks and SmallCap Sentinel |
|
a
It's been a little while since we published about this compelling story which is now trading at roughly $1 per share on heavy volume. The Business Week story has been well distributed across a spate of large biotech companies via news releases across the web. This will assuredly enhance CVBT's visibility and credibility in the emergent biotech industry.
If you'd like to review our previous profile on CVBT, their story and science please CLICK THIS LINK.
a
*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.
To learn more about our programs email us directly at info@stockupticks.com
Stockupticks Safe Harbor Statement: Statements contained in this document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP). MP provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. MP has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources believed by MP to be reliable, but MP provides no assurance, and none is given, as to the accuracy and completeness of this information.
Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP). The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP has been paid nineteen thousand two hundred dollars by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company. Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA 92614. MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement. Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results. The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned. Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated. |
|
